{
  "nctId": "NCT03305341",
  "briefTitle": "Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix",
  "officialTitle": "Conducting an Initial Small, Controlled Clinical Pharmacology Trial to Assess for Therapeutic Biologics Activity (Proof-of-Concept) That Suggests the Potential for Clinical Benefits of COVID-19 Patients With Controlled Cancers.",
  "protocolDocument": {
    "nctId": "NCT03305341",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2025-06-04",
    "uploadDate": "2025-06-06T13:50",
    "size": 1089789,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT03305341/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "EARLY_PHASE1"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NA",
  "interventionModel": "SINGLE_GROUP",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 20,
    "enrollmentType": "ESTIMATED"
  },
  "timeline": {
    "startDate": "2025-05-18",
    "completionDate": "2026-07-28",
    "primaryCompletionDate": "2026-07-18",
    "firstSubmitDate": "2017-10-04",
    "firstPostDate": "2017-10-09"
  },
  "eligibilityCriteria": {
    "criteria": "* Conducting an initial small, controlled trial to assess therapeutic biologics activity (proof-of-concept) that suggests the potential for clinical benefit of COVID-19 patients with controlled cancers.\n* 20 Moderate COVID-19 patients with controlled cancers\n\nInclusion Criteria:\n\n* Controlled Cancers\n* Moderate COVID-19\n* Positive testing by standard RT-PCR assay or equivalent testing\n* Symptoms of moderate illness with COVID-19, which could include any symptom of mild illness or shortness of breath with exertion\n* Clinical signs suggestive of moderate illness with COVID-19, such as respiratory rate ≥ 20 breaths per minute, saturation of oxygen (SpO2) \\> 93% on room air at sea level, heart rate ≥ 90 beats per minute\n* No clinical signs indicative of Severe or Critical Illness Severity\n\nExclusion Criteria:\n\n* 1\\. Uncontrolled Cancers\n* 2\\. Severe or Critical Illness Severity\n* 3\\. Pregnancy\n* 4\\. Breast-feeding\n* 5\\. The patients with other serious inter-current illness\n* 6\\. Serious Allergy\n* 7\\. Serious Bleed Tendency\n* 8\\. The prohibition of the biological product",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "24 Years",
    "maximumAge": "64 Years",
    "stdAges": [
      "ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Number of Participants with Moderate COVID-19:",
        "description": "* 20 Moderate COVID-19 patients with controlled cancers\n* Moderate COVID-19\n* Positive testing by standard RT-PCR assay\n* Symptoms of moderate illness with COVID-19, which could include any symptom of mild illness or shortness of breath with exertion\n* Clinical signs suggestive of moderate illness with COVID-19, such as respiratory rate ≥ 20 breaths per minute, saturation of oxygen (SpO2) \\> 93% on room air at sea level, heart rate ≥ 90 beats per minute\n* No clinical signs indicative of Severe or Critical Illness Severity",
        "timeFrame": "Duration at least 28 days"
      },
      {
        "measure": "Rate of Positive COVID-19 nucleic acid:",
        "description": "* 20 Moderate COVID-19 patients with controled cancers\n* Positive testing COVID-19 by standard RT-PCR assay immediately\n* COVID-19 nucleic acid testing, assessed by RT-PCR Assay Kit\n* Rate of Positive COVID-19 nucleic acid must be 100%",
        "timeFrame": "Duration at least 28 days"
      },
      {
        "measure": "Rate of Negative COVID-19 nucleic acid",
        "description": "* 20 Moderate COVID-19 patients with controlled cancers\n* NOVAVAX COVID-19 VACCINE 1.0 mL plus BCG Organism 50 MG Mix\n* By the percutaneous route with the multiple puncture device\n* Negative COVID-19 by standard RT-PCR assay after percutaneous use 3 weeks\n* COVID-19 nucleic acid testing, assessed by RT-PCR Assay Kit\n* Rate of Negative COVID-19 nucleic acid will be more than 80%",
        "timeFrame": "Duration at least 28 days"
      },
      {
        "measure": "20 COVID-19 Participants with IGRA blood test with COVID-19 spike protein antigen",
        "description": "Positive IGRA blood test with COVID-19 spike protein antigen after percutaneous use 21 days",
        "timeFrame": "Duration at least 28 days"
      },
      {
        "measure": "20 COVID-19 Participants with IGRA blood test with TB antigens",
        "description": "* Negative IGRA blood test with TB antigens before percutaneous use\n* Positive IGRA blood test with TB antigens after percutaneous use 21 days",
        "timeFrame": "Duration at least 28 days"
      }
    ],
    "secondary": [],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 5,
      "secondaryCount": 0,
      "otherCount": 0,
      "totalCount": 5
    },
    "studyDesign": {
      "phases": [
        "EARLY_PHASE1"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "SINGLE_GROUP"
    },
    "overallComplexityScore": 54,
    "complexityCategory": "Complex"
  },
  "collectionDate": "2025-09-22T02:30:37.165Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}